Jeffrey T L Smith
CIK 1604800 · EVP & Chief Medical Officer · last filed 2026-01-12
Jeffrey T L Smith is an EVP & Chief Medical Officer who has filed 46 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing, for ZYME, was dated Mar 6, 2026. Across all open-market trades the lifetime net is −$7.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $876.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$876.0K
2
46
-$7.56M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZYME | EVP & Chief Medical Officer | 36,018 | $24.32 | $876.0K | -$641.4K | 5 | 2026-01-12 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Managing Director | 5,272 | — | — | -$6.92M | 36 | 2019-09-18 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-06 | ZYME | Notice (144) | −247,333 | -$6.13M | EDGAR |
| 2026-01-12 | ZYME | Mixed | +8,356 | -$211.1K | EDGAR |
| 2026-01-12 | ZYME | Notice (144) | −9,310 | -$215.7K | EDGAR |
| 2026-01-05 | ZYME | Mixed | +9,462 | -$264.5K | EDGAR |
| 2026-01-05 | ZYME | Notice (144) | −10,538 | -$280.5K | EDGAR |
| 2025-01-10 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | ZYME | Mixed | +8,890 | -$165.8K | EDGAR |
| 2025-01-06 | ZYME | Notice (144) | −11,110 | -$160.7K | EDGAR |
| 2024-01-08 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2019-10-24 | — | Mixed | −5,272 | -$387.0K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.